Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Off-Label Communications Bill Allowing Discussion Of Unapproved Drugs Advances

Executive Summary

Safe harbor for off label discussions between manufacturers and payers clears US House Energy & Commerce Health Subcommittee. Bill covers unapproved drugs as well as off label uses for approved agents.

Advertisement

Related Content

Opioid, NME, And Generic Drugs Changes Plotted In US FDA's 2018 Policy Roadmap
Opioid, NME, And Generic Drugs Changes Plotted In US FDA's 2018 Policy Roadmap
Industry Communications With Payors: US FDA Okays Info On Investigational Drugs
'Safe Harbor' For Preapproval Information Exchange To Get Legislative Push

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122340

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel